Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Melanie Davies, MD, PhD
Credit: American Diabetes Association

AstraZeneca announced positive Phase 2b results for elecoglipron, an investigational oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), across two trials in obesity and 

, paving the way for an extensive Phase 3 program.

Results from the VISTA and SOLSTICE trials were presented at the 

American Diabetes Association (ADA) 2026 Scientific Sessions

 in New Orleans and simultaneously published in 

“The progression of elecoglipron is an important step in delivering a differentiated weight management portfolio, offering monotherapies and combinations, designed to address the biological complexity of obesity and comorbidities that can be tailored to individual needs, enabling people to live healthier lives,” said Sharon Barr, executive vice president of BioPharmaceuticals Research and Development at AstraZeneca. “These results give us confidence as we kick off our extensive Phase 3 programme.”

Elecoglipron is an investigational oral, once-daily small molecule GLP-1 receptor agonist in development by AstraZeneca for obesity, overweight, and type 2 diabetes, without food or fasting restrictions.

What did the VISTA trial show for elecoglipron?

In VISTA, adults with obesity or overweight receiving elecoglipron 75 mg achieved an average 10.5% reduction in body weight at 26 weeks versus 0.6% with placebo, with weight loss continuing to 11.8% at 36 weeks.

What were the SOLSTICE trial results for elecoglipron in type 2 diabetes?

In SOLSTICE, elecoglipron 75 mg reduced HbA1c by an average of 1.9% from baseline at 26 weeks versus 0.2% with placebo, with 90% of treated participants reaching an HbA1c below 7%.

The oral GLP-1 RA class has drawn considerable attention given adherence and accessibility advantages over injectable formulations. Elecoglipron, dosed once daily without food or fasting restrictions, advances AstraZeneca's cardiometabolic pipeline alongside plans for combination regimens with dapagliflozin and dedicated cardiovascular and kidney outcome trials.

Elecoglipron safety profile and glycemic outcomes in VISTA

VISTA enrolled 310 adults with obesity or overweight and at least one comorbidity across seven countries (mean baseline weight 106.9 kg). The trial used a randomized, parallel-group, double-blind design evaluating multiple elecoglipron dose regimens versus placebo, with all participants receiving standardized diet and physical activity advice. The co-primary endpoints were percent change in body weight and the proportion of participants achieving at least 5% weight loss, both measured from baseline to 26 weeks.

At the highest dose (75 mg, weekly escalation), elecoglipron produced an average body weight reduction of 10.5% at 26 weeks versus 0.6% with placebo, meeting one primary endpoint.

 Weight loss continued without plateau to 11.8% at 36 weeks versus 0.3% with placebo.

 The proportion of participants achieving at least 5% weight loss at 26 weeks reached 88.8% with elecoglipron 75 mg versus 15.6% with placebo, meeting the second co-primary endpoint.

In exploratory analyses, elecoglipron also produced clinically meaningful reductions in blood pressure and C-reactive protein levels.

Elecoglipron safety profile and glycemic outcomes in SOLSTICE

SOLSTICE enrolled 404 adults with type 2 diabetes across 9 countries with a primary endpoint of change in HbA1c from baseline to 26 weeks. Elecoglipron 75 mg reduced HbA1c by an average of 1.9% from baseline at 26 weeks versus 0.2% with placebo.

Among participants with baseline HbA1c of at least 7%, 90% receiving elecoglipron 75 mg achieved an HbA1c below 7% and 85% achieved an HbA1c of 6.5% or lower by 26 weeks. Elecoglipron 75 mg also produced a 7.7% reduction in body weight versus 1.7% with placebo in SOLSTICE.

The safety profile across both trials was consistent with the GLP-1 RA class, with adverse events predominantly gastrointestinal and of mild to moderate severity. In VISTA, nausea occurred in 55% of participants on elecoglipron 75 mg versus 20% on placebo; constipation occurred in 41% versus 6%; diarrhea in 35% versus 25%; and vomiting in 29% versus 5%. Rates in SOLSTICE were lower across all 4 GI events.

Adverse events leading to discontinuation were infrequent in both trials, no liver safety signals were observed, and hypoglycemia was uncommon in SOLSTICE with no serious hypoglycemic events attributed to elecoglipron.

 AstraZeneca noted the Phase II tolerability data have informed the dose escalation schedule for Phase III to further refine the tolerability profile.

"The VISTA results show people receiving once-daily oral elecoglipron achieved significant weight loss as well as lower blood pressure and systemic inflammation, demonstrating its potential to treat both obesity and its related complications," said Melanie Davies, Professor of Diabetes Medicine at University of Leicester and VISTA Principal Investigator.

According to their press release, AstraZeneca is advancing elecoglipron into the EMBOLD Phase III trials evaluating the agent in obesity and overweight, with and without type 2 diabetes, and the ELUMINATE Phase III trials evaluating elecoglipron as monotherapy and in combination with dapagliflozin in type 2 diabetes. Additional outcome trials targeting long-term cardiovascular and kidney endpoints are also planned.

AstraZeneca. Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca's cardiometabolic and kidney portfolio. Published June 8, 2026. Accessed June 9, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/elecoglipron-an-oral-small-molecule-glp-1-ra-moves-to-phase-iii-programme.html

Davies M, et al. Elecoglipron in adults with obesity or overweight (VISTA): a phase 2b randomised controlled trial. 

Articles

Phase 2b data support once-daily oral elecoglipron, a small-molecule GLP‑1 receptor agonist, as a potential obesity and type 2 diabetes therapy. In VISTA (n=310), 75 mg achieved 10.5% weight loss at week 26 and 11.8% at week 36, with 88.8% reaching ≥5% loss, plus exploratory reductions in blood pressure and CRP. In SOLSTICE (n=404), 75 mg lowered HbA1c by 1.9% and reduced weight 7.7%. GI events predominated; discontinuations were uncommon, without liver signals or meaningful hypoglycemia. Presented at ADA 2026 and published in The Lancet, results enable Phase 3 programs.

Elecoglipron 75 mg produced 10.5% body weight reduction at 26 weeks in VISTA and a 1.9% HbA1c reduction at 26 weeks in SOLSTICE.

Type 2 Diabetes

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Elecoglipron Advances to Phase 3, Shows Phase 2 Weight Loss, Glycemic Data

Gerard Criner, MD, is chair and professor of thoracic medicine and surgery at Lewis Katz School of Medicine at Temple University and director of the Temple Lung Center.

Pegtarazimod Reduces Supplemental Oxygen Need in Hospitalized AE-COPD Patients

A phase 2 proof-of-concept trial presented at the 

American Thoracic Society (ATS) 2026 International Conference

 in Orlando, Florida, found that pegtarazimod (RLS-0071), a dual-acting anti-inflammatory peptide, reduced supplemental oxygen requirements and improved oxygenation metrics in hospitalized patients with 

, with a durable effect extending out to 60 days post-dose.

Gerard J. Criner, MD, ATSF, FCCP, FACP, from Lewis Katz School of Medicine at Temple University, presented the findings and spoke with

at ATS 2026 about what the data mean for pulmonologists managing hospitalized COPD patients.

21 patients enrolled; 10 received pegtarazimod (10 mg/kg IV TID x 3–5 days) vs 11 placebo

Reduced FiO₂ requirements sustained through 60-day follow-up in the treatment group

ROX index and O2 saturation improved vs placebo; no safety signals identified

Patients with NLR > 9 showed the greatest gains in oxygenation and respiratory rate reduction

A Persistent Gap in Acute Exacerbation Management

Hospitalized AE-COPD events carry significant clinical consequences: accelerated lung function decline, reduced quality of life, and increased mortality. Despite this burden, Criner noted that no therapies specifically targeting the acute exacerbation event have materially advanced in more than 50 years.

Neutrophilic inflammation drives the biology of acute exacerbations, and no existing therapy has proven capable of shifting outcomes for hospitalized patients. Criner said an effective therapy for neutrophilic inflammation could “change the tide” in patients admitted to the hospital.

“Pegtarazimod…which is a drug that's been used for [the] treatment of refractory chronic graft versus host disease, might uniquely fill the void to decrease neutrophilic inflammation in patients admitted to the hospital with COPD,” Criner said.

The agent inhibits the classical pathway of complement along with 2 key neutrophil inflammatory effectors—myeloperoxidase (MPO) and neutrophil elastase (NE)—positioning it as a targeted approach to the neutrophil-driven pathophysiology underlying many hospitalized AECOPD events.

The trial was a randomized, double-blind, placebo-controlled study enrolling hospitalized adults with AE-COPD. A total of 21 patients were enrolled, with 11 randomized to placebo and 10 to pegtarazimod as add-on therapy to usual care. The dosing regimen was 10 mg/kg IV 3 times daily for ≥ 3 days and up to 5 days. Participants were followed for efficacy and safety at 30 and 60 days after the final dose.

Primary oxygenation outcomes included change in fraction of inspired oxygen (FiO₂), oxygen saturation (O₂ sat), respiratory rate, and the ROX index, a validated calculation of SpO₂/FiO₂/respiratory rate used to predict intubation risk in acute hypoxic respiratory failure, where higher values indicate improved oxygenation and reduced work of breathing.

Compared to placebo, patients receiving pegtarazimod required less supplemental oxygen during hospitalization, as measured by decreased FiO₂, with that benefit sustained through the 60-day follow-up window. The treatment group also demonstrated increased blood oxygen saturation and improved ROX index scores relative to controls.

"Patients treated with pegtarazimod had a sooner improvement in oxygen saturation, a decrease in oxygen requirements, a slight improvement in lung function, and also an improvement in quality of life," Criner said.

No safety concerns were identified over the study period.

When patients were stratified by neutrophil-to-lymphocyte ratio (NLR), those with a high NLR—defined as > 9, consistent with strongly neutrophil-driven disease—showed the greatest respiratory benefit. This subgroup demonstrated less supplemental oxygen need, larger decreases in respiratory rate, and greater increases in the ROX index compared to patients with NLR below 9, aligning with pegtarazimod's mechanism of action.

Criner noted that while the NLR findings are based on a small sample, they are consistent with data from larger studies examining NLR as a marker of neutrophil-driven inflammation. The accessibility of NLR as a standard clinical lab value, rather than a specialized assay, could make it a practical patient selection tool if findings hold in larger trials.

Criner outlined what a definitive trial would require. A phase 2b study would need expanded enrollment, longer follow-up (a minimum of 6 months), and predefined efficacy endpoints targeting both mechanistic and clinical outcomes.

If replicated at scale, pegtarazimod could represent the first targeted anti-inflammatory strategy specifically designed for the acute hospitalized COPD setting, addressing a therapeutic gap that has persisted for half a century.

At ATS 2026, Criner also presented on pooled phase 3 data showing mepolizumab reduced COPD exacerbations and hospitalizations in patients with blood eosinophil counts starting at 150 cells/µL. Watch the interview here: 

Mepolizumab Reduced COPD Exacerbations, With Gerard Criner, MD

Editor’s note: Relevant disclosures for Criner include Pulmonx Corporation, GENZYME CORPORATION, GlaxoSmithKline, Olympus Corporation of the Americas, F. Hoffmann-La Roche AG, and AstraZeneca Pharmaceuticals.

Criner G, David J, Sadikot R, et al. Pegtarazimod (RLS-0071) Decreases Supplemental Oxygen Need in a Phase 2 Proof-of-Concept Trial in Hospitalized Participants With Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AE-COPD). Poster presented at ATS 2026 in Orlando, Florida, on May 18, 2026. 

https://ats2026.d365.events/education/sessions/b1bea76b-7dbc-4de6-ad83-8c87fba81834

Criner G. Mepolizumab Reduced COPD Exacerbations, With Gerard Criner, MD. HCPLive. Published on May 19, 2026. Accessed June 9, 2026. 

https://www.hcplive.com/view/mepolizumab-reduced-copd-exacerbations-gerard-criner-md

Videos

Phase 2 findings presented at ATS 2026 by Gerald Criner, MD, show pegtarazimod cut supplemental oxygen needs in hospitalized AE-COPD patients for up to 60 days.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Pegtarazimod Reduces Supplemental Oxygen Need in Hospitalized AE-COPD Patients 

The Influence of Physician Role Models on Young Patients, With Lisa Swanson, MD

 explored the lasting influence physicians can have on young patients, particularly through representation, mentorship, and the relationships formed over years of care.

Hosted by Mona Shahriari, MD, associate clinical professor of dermatology at Yale University and practicing dermatologist in Connecticut, the discussion featured Lisa Swanson, MD, a dual board-certified dermatologist and pediatric dermatologist at Ada West Dermatology and St. Luke’s Children’s Hospital in Boise, Idaho.

As the episode drew to a close, Shahriari reflected on one of the unique aspects of caring for children: their ability to bring humor, curiosity, and joy into the clinical setting. She noted that pediatric patients often find delight in seemingly ordinary moments and can help physicians reconnect with a lighter perspective on life. The conversation naturally transitioned into a discussion about the impact physicians may have on young patients who see them not only as healthcare providers but also as role models.

Swanson reflected on her own experience as a child patient, recalling how a dermatologist she admired helped shape her perception of what was possible professionally. Looking back, she recognized the influence that seeing a successful woman physician had on her eventual decision to pursue dermatology herself. That experience, she explained, has made her acutely aware that some of the children she treats today may similarly remember their interactions with her for years to come.

To illustrate that point, Swanson shared the story of a young patient with severe alopecia areata. After receiving treatment and experiencing substantial hair regrowth, the child returned to clinic excited to show off a new haircut. For Swanson, the moment represented far more than a successful therapeutic outcome. The experience became even more meaningful when the child later asked whether she could become a dermatologist someday. Swanson described immediately encouraging the young girl, viewing the interaction as a reminder of the broader influence physicians can have beyond diagnosis and treatment.

Shahriari emphasized that many clinicians may underestimate the significance of their presence in patients’ lives, particularly for children who may view their physicians as heroes. She suggested that representation matters not only in terms of professional achievement but also in demonstrating compassion, confidence, and leadership.

Swanson also reflected on the relationships that develop with pediatric patients and their families over time. She described feeling honored when families mention discussing her outside of clinic visits, seeing those moments as evidence that she has become a meaningful part of their lives.

Together, Shahriari and Swanson concluded that the influence of a physician often extends well beyond medical care, shaping how children view themselves, their futures, and the possibilities available to them.

Editor’s note: This episode was produced with the help of AI tools.

Want to join The Medical Sisterhood community? Click here to join our LinkedIn Group!

Swanson L, Shahriari M. The Medical Sisterhood: The Hidden Cost of Being the Compassionate Doctor, With Lisa Swanson MD. HCPLive. May 15, 2026. Accessed June 9, 2026. 

https://www.hcplive.com/view/the-medical-sisterhood-hidden-cost-compassionate-doctor-lisa-swanson-md

This segment of the May episode of The Medical Sisterhood highlights key points regarding the impacts of role models on young patients in dermatology.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Aboul-Fettouh describes the protracted path many patients travel before receiving a correct AA diagnosis-often 6 to 12 months or longer-and explains the psychosocial weight that accumulates during that delay.

The Patient Journey to Diagnosis: Delays, Barriers, and the Psychosocial Toll

Patients with alopecia areata often endure a prolonged and frustrating diagnostic odyssey before they reach a dermatologist who can offer a definitive assessment and a structured therapeutic plan. In the most favorable scenario, a patient notices new hair loss, promptly seeks care, and is seen by a dermatologist who makes the correct diagnosis within weeks. This best-case trajectory, while achievable, is not the norm.

More commonly, patients spend months-and in many cases more than a year— attempting over-the-counter remedies marketed for hair loss, consulting generalist physicians who may not immediately recognize AA, and researching their symptoms online in a cycle that generates anxiety without generating answers. By the time many of these patients arrive at a dermatologist's office, they have already exhausted significant time, energy, and often money chasing treatments that were never suited to an autoimmune etiology.

The consequences of delayed diagnosis extend well beyond the scalp and carry meaningful clinical weight. Patients who have been symptomatic for 6 to 12 months or longer without a diagnosis have typically begun to restructure their lives around their hair loss: wearing hairpieces or head coverings as a daily necessity, declining social invitations that might involve scrutiny of their appearance, and experiencing escalating anxiety or depression that compounds the primary disease burden. The psychosocial impact of AA is not incidental or secondary—it constitutes a core, measurable dimension of the disease. Standardized instruments such as the Dermatology Life Quality Index (DLQI) consistently capture significant impairment in AA populations, and this impairment deepens with every additional month that an accurate diagnosis and effective treatment are deferred. Dermatologists who appreciate this trajectory are better equipped to meet newly referred patients with the urgency and empathy that their situation warrants.

In this segment, Nader Aboul-Fettouh, MD, double board-certified dermatologist and fellowship-trained Mohs Micrographic Surgeon and founder and managing director of Blue Ribbon Dermatology in the Dallas area, outlines the typical patient journey to an AA diagnosis, drawing on his clinical experience to describe the accumulating burden-practical, emotional, and social-that patients carry by the time they reach specialized dermatologic care. He emphasizes that even in an era of highly effective therapies, too many individuals are arriving later than is ideal and already struggling with significant, measurable quality-of-life impairment.

Video Series

Aboul-Fettouh clarifies the broad meaning of "alopecia" as a category, distinguishes alopecia areat as an autoimmune subtype, and addresses common patient misconceptions-including misplaced self-blame-that complicate early education and care.

Understanding Alopecia Areata: Terminology, Misconceptions, and Patient Education

The term "alopecia" describes hair loss broadly and serves as an umbrella for dozens of distinct conditions rather than a single diagnosis. Androgenetic alopecia, traction alopecia, telogen effluvium, and alopecia areata are all forms of alopecia, yet each has a fundamentally different etiology, prognosis, and therapeutic approach. This distinction matters enormously in clinical practice: a patient who reports "I have alopecia" has provided the dermatologist with a descriptive term, not a diagnosis. The specific subtype drives management decisions, patient education priorities, and realistic conversations about what treatment can and cannot accomplish. Among all subtypes, alopecia areata (AA) stands out as an autoimmune process in which the body's own immune cells target the hair follicle, producing characteristic bald patches, diffuse thinning, or, in its most severe forms, complete scalp or total body hair loss.

A particularly consequential and persistent misconception is the belief-common among newly diagnosed patients-that their own behavior triggered or worsened the disease.

Patients frequently wonder whether their diet, specific medications, an emotionally difficult period, or accumulated stress caused the follicular destruction they are experiencing. The reality is that AA reflects a combination of genetic predisposition and immune dysregulation; it is not caused or meaningfully worsened by anything the patient ate, took, or felt. Dermatologists managing AA must emphasize this point clearly and, often, repeatedly. Cultural stigmas surrounding visible hair loss can intensify self-blame and amplify the emotional burden of an already distressing diagnosis, making empathetic, corrective counseling an integral-not optional-component of every early clinical encounter. Patients who understand that they did not cause their disease are better positioned to engage with treatment and adhere to long-term therapy.

In this segment of a video discussion on alopecia areata, Nader Aboul-Fettouh, MD, double board-certified dermatologist and fellowship-trained Mohs Micrographic Surgeon and founder and managing director of Blue Ribbon Dermatology in the Dallas area, explains the critical distinction between the generic term "alopecia" and the specific autoimmune entity "alopecia areata." He also describes how he approaches the patient who arrives at the dermatology office already burdened by unwarranted guilt about their condition, and why correcting that narrative early is foundational to the entire therapeutic relationship.

Learn how Rome V criteria and gut–brain insights clarify pediatric constipation vs IBS-C, reducing unnecessary tests and guiding targeted pain care.

Distinguishing Functional Constipation From IBS-C and Embracing a Positive Diagnosis

Robert Wallis, MD, is the chief scientific officer at the Aurum Institute and adjunct professor in the department of medicine at Vanderbilt University Medical Center.

At ATS 2026, Robert Wallis, MD, discussed PanTB-HM findings on FEV1 recovery and NAC antimicrobial interactions.

Sutezolid Shows Promise as Safer Oxazolidinone in Novel 4-Month TB Regimen

Henry Lim, MD, is the senior vice president of academic programs at Henry Ford Health. He previously served as chair of the department of dermatology.

This segment of the latest Skin of Color Savvy episode highlights clinician viewpoints surrounding sun protection and skin cancer.

How Inclusive Messaging Could Improve Skin Cancer Prevention

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Ketan Dhatariya, MD, PhD, MS, joins the show to discuss how therapies for diabetes have evolved in the UK in comparison to the US.

Type 1 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Diabetes Dialogue: Diabetes Technology and Treatment in the UK, With Ketan Dhatariya, MD, PhD, MS

Njira Lugogo, MD, from University of Michigan.

Phase 4 PASSAGE data from ATS 2026 show tezepelumab reduced exacerbation rates across a diverse real-world cohort, including smokers, adolescents, and patients with comorbid COPD.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

Tezepelumab Reduces Severe Asthma Exacerbations by 70% in Phase 4 PASSAGE

twiist improved time in range by 16 percentage points and reduced HbA1c by 0.7 points over 13 weeks in insulin-treated adults with type 2 diabetes, with no severe hypoglycemia events.

twiist AID System Improves HbA1c, Time in Range in Insulin-Treated Type 2 Diabetes

Dr. Kiera Booth, MD, is a board-certified dermatologist practicing at Premier Dermatology & Cosmetic Surgery in the Newark and Middletown, Deleware areas.

This Q&A interview highlights key takeaways regarding hidradenitis suppurativa, raising awareness for HS Awareness week, and the current treatment landscape.

Hidradenitis Suppurativa

Hidradenitis Suppurativa condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatology research, treatment, and drug development.

Q&A: How Does the Current HS Landscape Look? With Kiera Booth, MD

In the phase 2 SLIMMER-UP-SWITCH trial, ecnoglutide delivered greater weight loss and waist circumference reduction than semaglutide at 20 weeks in adults with obesity in China.

Ecnoglutide Delivers 35% Greater Weight Loss Than Semaglutide in Head-to-Head Trial

Trang Ly, PhD, MBBS, joins the show to discuss Insulet’s recent advancements in automated insulin delivery and the trajectory of the Omnipod platform.

Diabetes Dialogue: Omnipod and AID Advancements at Insulet, With Trang Ly, PhD, MBBS

DKA remains a growing challenge in diabetes care, with new data highlighting missed diagnoses, rising admissions, and higher costs.

Latest News

Elecoglipron Advances to Phase 3, Shows Phase 2 Weight Loss, Glycemic Data

Pegtarazimod Reduces Supplemental Oxygen Need in Hospitalized AE-COPD Patients

The Influence of Physician Role Models on Young Patients, With Lisa Swanson, MD

The Patient Journey to Diagnosis: Delays, Barriers, and the Psychosocial Toll

Understanding Alopecia Areata: Terminology, Misconceptions, and Patient Education